Incidence ,
暂无分享,去创建一个
S. Pocock | T. Henry | M. Krucoff | G. Dangas | G. Weisz | R. Mehran | A. Kini | U. Baber | A. Colombo | B. Vogel | D. Cohen | P. Steg | D. Moliterno | S. Sartori | J. Chandrasekhar | M. Faggioni | M. Aquino | B. Witzenbichler | S. Farhan | G. Giustino | A. Chieffo | C. Ariti | D. Giacoppo | M. Gibson | D. Cohen
[1] Laura Lovato,et al. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study , 2016, American Journal of Nephrology.
[2] S. Pocock,et al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.
[3] W. Weaver,et al. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study , 2016, Circulation.
[4] V. Ritsinger,et al. High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: Results From the Swedish Coronary Angiography and Angioplasty Registry , 2015, Circulation. Cardiovascular interventions.
[5] F. Pomero,et al. Is diabetes a hypercoagulable state? A critical appraisal , 2015, Acta Diabetologica.
[6] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[7] Antonio Colombo,et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.
[8] Deepak L. Bhatt,et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.
[9] Antonio Colombo,et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.
[10] Y. Jang,et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.
[11] Samin K. Sharma,et al. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. , 2012, Journal of interventional cardiology.
[12] M. Jeong,et al. Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.
[13] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[14] Philippe Joly,et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach , 2011, Nature Genetics.
[15] J. DeVries,et al. A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction , 2011, Diabetes Care.
[16] R. Lopes,et al. Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation. , 2011, The American journal of cardiology.
[17] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[18] K. Filion,et al. Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents , 2009, Circulation.
[19] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[20] Michal Abrahamowicz,et al. A proportional hazards model with time-dependent covariates and time-varying effects for analysis of fetal and infant death. , 2004, American journal of epidemiology.
[21] B. Sobel,et al. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. , 2003, The American journal of cardiology.
[22] A. Dreher. Modeling Survival Data Extending The Cox Model , 2016 .
[23] Preobrazhenskiĭ Dv. [Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents]. , 2010 .
[24] S. Schinner. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .